/EINPresswire.com/ - COLUMBUS, OH- - (Marketwired - Nov 28, 2016) - Sermonix Pharmaceuticals LLC, a forte pharmaceutical organization concentrated on the improvement and commercialization of female-particular oncology items, today reported that its notice on doctor view of estrogen agonist/rivals in menopausal wellbeing has been acknowledged for presentation at the San Antonio Breast Cancer Symposium (SABC).
The Dec. 6-10 meeting at the Henry B. Gonzalez Convention Center in San Antonio will incorporate the blurb "Doctor Perceptions of Estrogen Agonist/Antagonists in Menopausal Health: A Survey to Address Osteoporosis, Urogenital Health and Breast Concerns in Menopause and Breast Cancer Survivorship."
The blurb's exhibiting creators are:
Shari Goldfarb, M.D., Medical Oncologist, Memorial Sloan Kettering Cancer Center
Michael Krychman, M.D., Executive Director of the Southern California Center for Sexual Health and Survivorship Medicine in Newport Beach, California; Medical Director, Sexual Medicine, Hoag Hospital, Newport Beach, California
Paul Plourde, M.D., Sermonix Oncology Team Leader
David Portman, M.D., Sermonix Chief Executive Officer and Chief Medical Officer
Among the study's discoveries was that of ladies experiencing vulvovaginal decay (VVA), a normal of only 16 percent are accounted for to be treated with a specific estrogen receptor modulator (SERM).
"Side effects of vaginal decay have an extreme inconvenient effect on bosom disease survivors' personal satisfaction and ought not be overlooked," said Dr. Krychman. "Aromatase inhibitors, specifically, have a genuine negative wellbeing sway for ladies even after adjuvant endocrine treatment is stopped. There is a requirement for a non-estrogen treatment, for example, oral lasofoxifene, which these ladies can take for reestablishing both their bones and their urogenital wellbeing while conceivably ensuring their bosoms."
Oral lasofoxifene, Sermonix's lead investigational medication, is a third-era SERM, otherwise called an estrogen agonist/enemy. It's a standout amongst the most all around concentrated on medications in its classification, having been assessed in more than 15,000 ladies in an exhaustive overall stage I-III clinical improvement program that incorporates the PEARL, OPAL and different trials, demonstrating a positive effect on VVA notwithstanding a lessening in the danger of vertebral and non-vertebral cracks.
Sermonix is presently centered around creating lasofoxifene for bosom and ovarian disease treatment, especially a sign in cutting edge Estrogen Receptor positive (ER+) endocrine-safe bosom tumor. 70% of the more than 240,000 U.S. ladies every year determined to have bosom malignancy are ER+ and there are an expected 3 million living bosom disease survivors.
"There are neglected needs in the bosom malignancy survivorship populace as it identifies with osteoporosis and urogenital wellbeing," said Dr. Goldfarb. "The uplifting news is that we have medicines for bosom malignancy. Be that as it may, a significant number of these treatments make interminable conditions that antagonistically affect bosom malignancy survivors' bones and vagina."
Lasofoxifene is being examined for the treatment of metastatic bosom malignancy and, if discovered viable, will can possibly give ladies an enhanced contrasting option to existing endocrine medicines.
"The aftereffects of this doctor review highlight the neglected restorative needs ladies have amid and after endocrine treatment of their bosom malignancy," said Dr. Plourde. "Against estrogens have been the foundation of ER+ bosom disease for a considerable length of time, yet doctors have overlooked the effect such treatment has on personal satisfaction. Oral lasofoxifene is a novel investigational specialist with a solid hostile to estrogen impact on bosom. It likewise has valuable estrogenic consequences for the vagina and bone that mitigates bone misfortune and indications identified with vaginal decay."
About Sermonix
Sermonix Pharmaceuticals LLC is a forte pharmaceutical organization with a focused on center towards bringing female-particular oncology items through evidence of idea, preclinical and clinical advancement with a reasonable administrative pathway set up. The organization was established in 2014 by David Portman, MD, a main clinical scientist and master in ladies' wellbeing, menopause and specific estrogen receptor modulator (SERM) treatment. Sermonix has as its lead item oral lasofoxifene, with select permitting rights for the U.S. what's more, Japan got from Ligand Pharmaceuticals, Inc. The Sermonix interior administration group, drove by Dr. Portman, has noteworthy involvement in all phases of the medication improvement and administrative process.
James Symons, MS, PhD, is Vice President of Clinical Development at Sermonix. Paul Plourde, MD, Sermonix Oncology Team Leader, was already with Astra-Zeneca, where he was instrumental in the improvement and endorsement of both tamoxifen and Arimidex®. Elizabeth Attias, MMSc, ScD, is Vice President of Business Development. Miriam Portman, M.D., is the Chief Operating Officer of Sermonix. She is previous Co-executive and Founder of the Columbus Center for Women's Health Research. Sermonix Non-Executive Chairman of the Board is Anthony Wild, PhD, previous president of both Parke-Davis Pharmaceuticals and Warner-Lambert's Pharmaceutical Division.
The Dec. 6-10 meeting at the Henry B. Gonzalez Convention Center in San Antonio will incorporate the blurb "Doctor Perceptions of Estrogen Agonist/Antagonists in Menopausal Health: A Survey to Address Osteoporosis, Urogenital Health and Breast Concerns in Menopause and Breast Cancer Survivorship."
The blurb's exhibiting creators are:
Shari Goldfarb, M.D., Medical Oncologist, Memorial Sloan Kettering Cancer Center
Michael Krychman, M.D., Executive Director of the Southern California Center for Sexual Health and Survivorship Medicine in Newport Beach, California; Medical Director, Sexual Medicine, Hoag Hospital, Newport Beach, California
Paul Plourde, M.D., Sermonix Oncology Team Leader
David Portman, M.D., Sermonix Chief Executive Officer and Chief Medical Officer
Among the study's discoveries was that of ladies experiencing vulvovaginal decay (VVA), a normal of only 16 percent are accounted for to be treated with a specific estrogen receptor modulator (SERM).
"Side effects of vaginal decay have an extreme inconvenient effect on bosom disease survivors' personal satisfaction and ought not be overlooked," said Dr. Krychman. "Aromatase inhibitors, specifically, have a genuine negative wellbeing sway for ladies even after adjuvant endocrine treatment is stopped. There is a requirement for a non-estrogen treatment, for example, oral lasofoxifene, which these ladies can take for reestablishing both their bones and their urogenital wellbeing while conceivably ensuring their bosoms."
Oral lasofoxifene, Sermonix's lead investigational medication, is a third-era SERM, otherwise called an estrogen agonist/enemy. It's a standout amongst the most all around concentrated on medications in its classification, having been assessed in more than 15,000 ladies in an exhaustive overall stage I-III clinical improvement program that incorporates the PEARL, OPAL and different trials, demonstrating a positive effect on VVA notwithstanding a lessening in the danger of vertebral and non-vertebral cracks.
Sermonix is presently centered around creating lasofoxifene for bosom and ovarian disease treatment, especially a sign in cutting edge Estrogen Receptor positive (ER+) endocrine-safe bosom tumor. 70% of the more than 240,000 U.S. ladies every year determined to have bosom malignancy are ER+ and there are an expected 3 million living bosom disease survivors.
"There are neglected needs in the bosom malignancy survivorship populace as it identifies with osteoporosis and urogenital wellbeing," said Dr. Goldfarb. "The uplifting news is that we have medicines for bosom malignancy. Be that as it may, a significant number of these treatments make interminable conditions that antagonistically affect bosom malignancy survivors' bones and vagina."
Lasofoxifene is being examined for the treatment of metastatic bosom malignancy and, if discovered viable, will can possibly give ladies an enhanced contrasting option to existing endocrine medicines.
"The aftereffects of this doctor review highlight the neglected restorative needs ladies have amid and after endocrine treatment of their bosom malignancy," said Dr. Plourde. "Against estrogens have been the foundation of ER+ bosom disease for a considerable length of time, yet doctors have overlooked the effect such treatment has on personal satisfaction. Oral lasofoxifene is a novel investigational specialist with a solid hostile to estrogen impact on bosom. It likewise has valuable estrogenic consequences for the vagina and bone that mitigates bone misfortune and indications identified with vaginal decay."
About Sermonix
Sermonix Pharmaceuticals LLC is a forte pharmaceutical organization with a focused on center towards bringing female-particular oncology items through evidence of idea, preclinical and clinical advancement with a reasonable administrative pathway set up. The organization was established in 2014 by David Portman, MD, a main clinical scientist and master in ladies' wellbeing, menopause and specific estrogen receptor modulator (SERM) treatment. Sermonix has as its lead item oral lasofoxifene, with select permitting rights for the U.S. what's more, Japan got from Ligand Pharmaceuticals, Inc. The Sermonix interior administration group, drove by Dr. Portman, has noteworthy involvement in all phases of the medication improvement and administrative process.
James Symons, MS, PhD, is Vice President of Clinical Development at Sermonix. Paul Plourde, MD, Sermonix Oncology Team Leader, was already with Astra-Zeneca, where he was instrumental in the improvement and endorsement of both tamoxifen and Arimidex®. Elizabeth Attias, MMSc, ScD, is Vice President of Business Development. Miriam Portman, M.D., is the Chief Operating Officer of Sermonix. She is previous Co-executive and Founder of the Columbus Center for Women's Health Research. Sermonix Non-Executive Chairman of the Board is Anthony Wild, PhD, previous president of both Parke-Davis Pharmaceuticals and Warner-Lambert's Pharmaceutical Division.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.